RU2018145776A - Комбинированные терапии модуляторами фарензоидного х-рецептора (fxr) - Google Patents
Комбинированные терапии модуляторами фарензоидного х-рецептора (fxr) Download PDFInfo
- Publication number
- RU2018145776A RU2018145776A RU2018145776A RU2018145776A RU2018145776A RU 2018145776 A RU2018145776 A RU 2018145776A RU 2018145776 A RU2018145776 A RU 2018145776A RU 2018145776 A RU2018145776 A RU 2018145776A RU 2018145776 A RU2018145776 A RU 2018145776A
- Authority
- RU
- Russia
- Prior art keywords
- optionally substituted
- heteroaryl
- alkylene
- aryl
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341487P | 2016-05-25 | 2016-05-25 | |
| US201662341482P | 2016-05-25 | 2016-05-25 | |
| US62/341,482 | 2016-05-25 | ||
| US62/341,487 | 2016-05-25 | ||
| PCT/US2017/034564 WO2017205684A1 (en) | 2016-05-25 | 2017-05-25 | Combination therapies with farnesoid x receptor (fxr) modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018145776A true RU2018145776A (ru) | 2020-06-26 |
| RU2018145776A3 RU2018145776A3 (cg-RX-API-DMAC10.html) | 2021-03-01 |
Family
ID=60412964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018145776A RU2018145776A (ru) | 2016-05-25 | 2017-05-25 | Комбинированные терапии модуляторами фарензоидного х-рецептора (fxr) |
Country Status (13)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019025228A2 (pt) * | 2017-06-02 | 2020-06-23 | Akarna Therapeutics, Ltd. | Compostos bicíclicos fundidos |
| US11524029B2 (en) | 2018-08-13 | 2022-12-13 | Viscera Labs, Inc. | Therapeutic composition and methods |
| US11590161B2 (en) | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
| JP2022514731A (ja) * | 2018-08-14 | 2022-02-15 | アヴォリント | 原発性硬化性胆管炎の処置方法 |
| WO2020081766A1 (en) * | 2018-10-18 | 2020-04-23 | Avolynt | Use of sglt2 inhibitors to treat primary sclerosing cholangitis |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| CN111825653A (zh) * | 2019-04-19 | 2020-10-27 | 安道麦马克西姆有限公司 | 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途 |
| CA3154488A1 (en) | 2019-08-23 | 2021-03-04 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CA3154391A1 (en) | 2019-09-12 | 2021-03-18 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| EP4061357A4 (en) * | 2019-11-22 | 2024-01-10 | Avolynt | Use of sglt2 inhibitors to treat primary billiary cholangitis |
| IL296100A (en) * | 2020-03-11 | 2022-11-01 | Dong A St Co Ltd | A medicinal preparation for the prevention or treatment of non-alcoholic steatohepatitis |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| US20220034871A1 (en) * | 2020-07-31 | 2022-02-03 | Daiichi Sankyo Company, Limited | Methods for administering pexidartinib |
| PE20231096A1 (es) | 2020-08-25 | 2023-07-18 | Lilly Co Eli | Polimorfos de un inhibidor de ssao |
| US20240319210A1 (en) * | 2020-12-18 | 2024-09-26 | Human Metabolomics Institute, Inc. | Application of neonatal biliary atresia biomarker and detection method for same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005009387A2 (en) * | 2003-07-23 | 2005-02-03 | X-Ceptor Therapeutics Inc. | Azepine derivatives as pharmaceutical agents |
| ATE526318T1 (de) * | 2005-12-19 | 2011-10-15 | Glaxosmithkline Llc | Farnesoid-x-rezeptor-agonisten |
| EP4137137A1 (en) * | 2010-05-26 | 2023-02-22 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| AU2015314830B2 (en) * | 2014-09-12 | 2021-01-07 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
| CA2968434A1 (en) * | 2014-11-21 | 2016-05-26 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| RU2021107054A (ru) * | 2015-03-26 | 2021-03-31 | Акарна Терапьютикс, Лтд. | Конденсированные бициклические соединения для лечения заболевания |
-
2017
- 2017-05-25 MX MX2018014024A patent/MX2018014024A/es unknown
- 2017-05-25 WO PCT/US2017/034564 patent/WO2017205684A1/en not_active Ceased
- 2017-05-25 RU RU2018145776A patent/RU2018145776A/ru not_active Application Discontinuation
- 2017-05-25 BR BR112018073460A patent/BR112018073460A2/pt not_active Application Discontinuation
- 2017-05-25 JP JP2018562106A patent/JP2019517478A/ja active Pending
- 2017-05-25 KR KR1020187037471A patent/KR20190040936A/ko not_active Ceased
- 2017-05-25 US US16/303,741 patent/US20200397798A1/en not_active Abandoned
- 2017-05-25 AU AU2017270221A patent/AU2017270221A1/en not_active Abandoned
- 2017-05-25 CA CA3025007A patent/CA3025007A1/en not_active Abandoned
- 2017-05-25 SG SG11201810290WA patent/SG11201810290WA/en unknown
- 2017-05-25 CN CN201780045766.3A patent/CN109843298A/zh active Pending
- 2017-05-25 EP EP17803627.3A patent/EP3463373A4/en not_active Withdrawn
- 2017-05-25 SG SG10202011660RA patent/SG10202011660RA/en unknown
-
2018
- 2018-11-21 IL IL263179A patent/IL263179A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018014024A (es) | 2019-08-29 |
| BR112018073460A2 (pt) | 2019-07-09 |
| AU2017270221A1 (en) | 2018-12-20 |
| EP3463373A4 (en) | 2020-04-22 |
| WO2017205684A1 (en) | 2017-11-30 |
| CN109843298A (zh) | 2019-06-04 |
| SG10202011660RA (en) | 2020-12-30 |
| JP2019517478A (ja) | 2019-06-24 |
| KR20190040936A (ko) | 2019-04-19 |
| EP3463373A1 (en) | 2019-04-10 |
| RU2018145776A3 (cg-RX-API-DMAC10.html) | 2021-03-01 |
| CA3025007A1 (en) | 2017-11-30 |
| US20200397798A1 (en) | 2020-12-24 |
| IL263179A (en) | 2018-12-31 |
| SG11201810290WA (en) | 2018-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517478A5 (cg-RX-API-DMAC10.html) | ||
| KR102904955B1 (ko) | Glp-1r 작용제 및 그의 용도 | |
| US12479853B2 (en) | HIV inhibitor compounds | |
| TW202317536A (zh) | 用於靶向pd-l1之方法及組成物 | |
| JP2021518413A5 (cg-RX-API-DMAC10.html) | ||
| JP6636539B2 (ja) | 変形性関節症の治療のためのadamts阻害剤としての5−[(ピペラジン−1−イル)−3−オキソ−プロピル]−イミダゾリジン−2,4−ジオン誘導体 | |
| ES2674531T3 (es) | Moduladores del receptor acoplado a la proteína g 40 (gpr40) de pirrolidina para el tratamiento de enfermedades como la diabetes | |
| JP6858984B2 (ja) | がんおよび糖尿病の治療に有用な6−ヘテロシクリル−4−モルホリン−4−イルピリジン−2−オン化合物 | |
| IL275002B2 (en) | Fatty acid derivatives for treating non-alcoholic steatohepatitis | |
| JP2020536911A (ja) | Hivプロテアーゼ阻害剤としての1−ベンジル−2−イミノ−4−フェニル−5−オキソイミダゾリジン誘導体 | |
| RU2016122908A (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| HRP20221437T1 (hr) | Agonisti receptora glp-1 i njihova upotreba | |
| RU2010119645A (ru) | Замещенные гетероциклом пиперазинодигидротиенопиримидины | |
| RU2014111055A (ru) | 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение | |
| CN107406416A (zh) | 新型取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途 | |
| HRP20110458T1 (hr) | Inhibitori rna-ovisne rna-polimeraze iz virusa hepatitisa c, te pripravci i liječenje u kojem se koriste | |
| AU2015239021A1 (en) | Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | |
| TW202328139A (zh) | 用於靶向pd-l1之方法及組成物 | |
| JP2019507770A (ja) | 2−アミノ−N−[7−メトキシ−2,3−ジヒドロイミダゾ−[1,2−c]キナゾリン−5−イル]ピリミジン−5−カルボキサミド類 | |
| JP2019507185A5 (cg-RX-API-DMAC10.html) | ||
| WO2021252555A1 (en) | Collagen 1 translation inhibitors and methods of use thereof | |
| JP2022509206A5 (cg-RX-API-DMAC10.html) | ||
| US20220340561A1 (en) | Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | |
| JP2017538711A5 (cg-RX-API-DMAC10.html) | ||
| JP2018522927A (ja) | ヒト免疫不全ウイルス複製の阻害剤としての5−(n−ベンジルテトラヒドロイソキノリン−6−イル)ピリジン−3−イル酢酸誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210820 |